{"name":"Monica Mita","slug":"monica-mita","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE50MklhdFBnUzBwTC1sZkNyekFxb2VCMUEtWThPcURxOWRiRWNxd2JlN2tqTkxVMmJOWGJDRXJDRFoySUxLcTJNYkJJZjBuWXJnOFJEblRFMWcySDY5QmtV?oc=5","date":"2024-06-01","type":"trial","source":"Nature","summary":"Inhibition of lysine acetyltransferase KAT6 in ER+HER2− metastatic breast cancer: a phase 1 trial | Nature Medicine - Nature","headline":"Inhibition of lysine acetyltransferase KAT6 in ER+HER2− metastatic breast cancer: a phase 1 trial | Nature Medicine","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNNWV0VENkRHBRZnhzV2RhUE5QMEQzV0dBa0dBM28tVGQ0TzYxc2tkaWVIYVdaTElFclRCbERiVzkyRmRIbUp4X293T1h0Zi1LNTJNdmF6MjRyckJ3Uk5wT1Z5WFpOV3JoWm9udUhsMzN3NEhfR3hBY1A4Q1pOMDhNcGlCMHJqWVVJN0oxbVZQMjFRUkJLZW9wdmRsTmxOcmliaVFPS1lKQnFYd01XR0NrY2NUSEZlZw?oc=5","date":"2024-04-25","type":"pipeline","source":"prnewswire.com","summary":"Hoag Family Cancer Institute Welcomes Oncology 'Power Couple' - prnewswire.com","headline":"Hoag Family Cancer Institute Welcomes Oncology 'Power Couple'","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQbjByNjVYcWtCN01yODBlanRvZ1RSTnJQYzlpZDVqdzYxTS1xaEtQVzF1SmRHc2s5bGttZndJVmxiQU1td05qak9tUkVjcG9PQ0Q3SlZDbG5PdTF0THIwYU12VXlBa205OVpETlpNb3NtUTRmekVjRlh3R1I0czVsdEt2RGRBWkl2QUdmbkp3?oc=5","date":"2021-08-13","type":"pipeline","source":"OncLive","summary":"Dr. Mita on Treatment Selection in ER+, HER2- Breast Cancer - OncLive","headline":"Dr. Mita on Treatment Selection in ER+, HER2- Breast Cancer","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}